Latest News

Ensign Group (ENSG) has quietly outperformed many healthcare peers this year, so the stock now invites a closer look at whether its strong long term returns still leave room for further upside. See our latest analysis for Ensign Group. Recent trading has cooled slightly, with a modest pullback from recent highs even as Ensign holds near $174.14. However, the 90 day share price return and multi year total shareholder returns still point to sustained momentum rather than a reversal. If Ensign’s...

If you are wondering whether Summit Therapeutics is still worth a closer look after its big run, or if you would just be buying into yesterday's hype, this article will walk you through what the current price really implies. Summit has cooled off recently, with the stock up 1.4% over the last week and 1.8% over the past month. However, that sits on top of a 469.6% gain over three years and 235.6% over five years, even though the 1 year return is slightly negative at 0.8%. Those moves have...

Recently, analysts have raised their earnings estimates for AvePoint, and the stock has received a top Zacks Rank, reflecting stronger confidence in its profit outlook. This shift follows an earlier post-earnings setback highlighted by Voya Investment Management, underscoring how changing sentiment and short interest trends can rapidly reshape perceptions of AvePoint’s prospects. Next, we’ll examine how this renewed analyst optimism around AvePoint’s earnings outlook influences the company’s...

Lands' End (LE) has just posted Q3 2026 results with revenue of about $317.5 million and basic EPS of $0.17, putting a clear profit on the board for the quarter. The company has seen quarterly revenue hold around the low $300 million mark over the last few periods, while basic EPS has swung from losses of roughly $0.27 and $0.17 earlier in 2026 to a modest profit this quarter, setting up a story that is increasingly about how much of that top line can translate into sustainable margins. See...

Bristol-Myers Squibb (BMY) has quietly pushed higher over the past month, even as its longer term returns remain underwhelming. That mix of recent momentum and lagging history is exactly what makes the stock interesting now. See our latest analysis for Bristol-Myers Squibb. Over the past year, Bristol-Myers Squibb’s share price return has been negative, but the recent 1 month and 3 month share price gains suggest sentiment is cautiously improving as investors reassess its pipeline and...

Amer Sports (NYSE:AS) has quietly put together a strong run, with the stock climbing about 34% year to date and roughly 51% over the past year as revenue and earnings growth pick up. See our latest analysis for Amer Sports. That move has been reinforced by a sharp 30 day share price return of about 31% and a 1 year total shareholder return just over 50%, suggesting momentum is building as investors lean into its growth story. If Amer Sports’ run has you thinking about what else could surprise...

If you are wondering whether BlackBerry is quietly turning into a value opportunity after years in the wilderness, this piece will walk through whether the current share price still leaves upside on the table. The stock has had a choppy ride, up 7.9% over the last week and 11.1% year to date. That sits alongside a 54.2% gain over the past year and a still hefty 42.0% decline over five years. Recently, investors have been refocusing on BlackBerry’s pivot toward cybersecurity software and...

If you are wondering whether Papa John's International at around $40.96 is a quietly mispriced opportunity or a value trap in plain sight, this breakdown is for you. The stock is down about 2.8% over the last week, roughly flat over the past month, and still sitting on a 10.5% slide over the past year and a steep 48.2% drop over three years, which indicates sentiment has been under pressure for a while. Recent headlines have focused on Papa John's ongoing strategy tweaks, from sharpening its...

DigitalOcean Holdings (DOCN) is back in focus after its Paperspace acquisition, a deal aimed squarely at beefing up AI infrastructure just as the company more than doubled its direct AI revenue and locked in extra data center capacity. See our latest analysis for DigitalOcean Holdings. That AI push seems to be resonating, with the 90 day share price return of 45.42 percent and a 1 year total shareholder return of 29.85 percent signalling that momentum is building rather than fading. If you...

How Has IBM Stock Been Performing Lately International Business Machines has been on many investors watchlists lately, raising the question of whether its current share price offers real value or if most of the upside has already been captured. With a long history and a renewed focus on hybrid cloud and AI, IBM is again at the center of the value versus growth debate. Over the last year, IBM shares have delivered a strong 37.5% return, with gains of 2.9% over the past week and 1.3% over the...

In late November 2025, Alibaba launched its Quark AI Glasses line in China, offering S1 and G1 models priced from ¥3,799 and ¥1,899, tightly integrated with its Qwen AI model, Qwen App, and core platforms like Alipay, Amap, Taobao, Fliggy, and major music services. This move shows how Alibaba is pushing Qwen beyond the cloud and into everyday consumer hardware, potentially deepening user engagement across its wider digital ecosystem. We’ll now examine how Alibaba’s push into Qwen-powered...

Analyst Downgrade Sparks Fresh Scrutiny Of Kohl's Stock Kohl's (KSS) slipped about 3% after a fresh analyst consensus tagged the stock with a Sell rating, pointing to expected drops in comparable and net sales alongside thinning cash reserves. See our latest analysis for Kohl's. Despite the downgrade, Kohl's recent 30 day share price return of 37.6% and roughly 67% year to date gain suggest strong short term momentum. However, the five year total shareholder return remains negative,...

UiPath (PATH) has been on investors’ radar after a strong quarter, where it flipped to GAAP profitability, lifted its outlook, and doubled down on AI partnerships that could extend its lead in automation. See our latest analysis for UiPath. That earnings beat and the flurry of AI integrations with players like Nvidia, Microsoft, Talkdesk, and Veeva have clearly shifted sentiment, with UiPath’s roughly 63% 3 month share price return and 29% one year total shareholder return signaling building...

Wondering if MercadoLibre is still a smart buy after its huge run, or if most of the upside is already priced in? You are not alone. That is exactly what this valuation deep dive is here to unpack. The stock has pulled back slightly in the short term, with a 2.0% drop over the last week and 1.6% over the last month. It is still up 17.5% year to date and 10.4% over the past year, with a 138.3% gain over three years. Recent headlines have focused on MercadoLibre expanding its fintech and...

On December 4, 2025, Kinross Gold Corporation repaid in full its outstanding 4.50% Senior Notes with a principal amount of US$500 million, bringing total debt repayments to US$1.50 billion across 2024 and 2025 and leaving US$750 million of Senior Notes outstanding, with the next maturity in 2033. This accelerated balance sheet cleanup highlights Kinross’s emphasis on reducing interest costs and financial risk, potentially giving it more room to fund projects and shareholder returns. With...

Barclays just bumped SiteOne Landscape Supply (SITE) up to Equal Weight, pointing to cleaner SG&A execution and steady pricing, while a fresh media partnership and continued analyst support are reshaping how investors are sizing up the stock. See our latest analysis for SiteOne Landscape Supply. Even with the Barclays upgrade and the new media partnership signaling operational and growth momentum, the stock’s 1 year total shareholder return of -14.88 percent and 90 day share price return of...

NexGen Energy’s Rook I uranium project in Canada has moved through a crucial phase, with an upcoming Canadian Nuclear Safety Commission federal hearing now set as a key regulatory milestone on its path toward full construction approval. This hearing marks an important test of NexGen’s ability to convert its tier-1 Athabasca Basin resource into a fully permitted uranium operation, a step closely watched by investors focused on long-term supply fundamentals. With this federal hearing...

Wondering if Kimberly-Clark at around $102.89 is a bargain hiding in plain sight or a value trap dressed up as a dividend staple? Let us break down what the current price is really implying about its future. The stock has slipped about 3.8% over the last week and is roughly 21.2% down year to date, leaving it about 19.5% lower than a year ago, which naturally raises questions about sentiment and opportunity. Much of the recent share price pressure has come as investors reassess defensive...

Enbridge (TSX:ENB) just extended its dividend growth streak to 31 years, with the board approving a higher quarterly payout that underscores steady cash flow visibility and keeps income focused investors paying close attention. See our latest analysis for Enbridge. Despite a slightly softer recent patch, with modest negative short term share price returns even after the latest dividend news, Enbridge’s year to date share price gain and strong multi year total shareholder returns suggest...

If you are wondering whether GE Vernova’s huge run up has already priced in the upside, or if there is still value on the table, you are not alone. The stock has climbed 3.9% over the last week and 8.7% in the past month, and is now up an eye catching 84.5% year to date and 91.4% over the last year. This naturally raises questions about how much future growth is already baked in. That surge has been fueled by growing investor enthusiasm around the company’s role in the global energy...

In early December 2025, Salesforce reported Q3 FY26 results showing higher revenue and earnings year over year, raised its full-year guidance, affirmed a quarterly cash dividend of US$0.416 per share, completed a multibillion‑dollar buyback tranche, and announced that Lumen Technologies’ David Ward will join as President and Chief Architect. The quarter also highlighted rapid AI adoption through the Agentforce platform, a global Agentforce Life Sciences win with AstraZeneca, and a US$25...

In early December 2025, Galapagos NV reported updated Phase 2 ATALANTA-1 data showing high complete response rates and durable outcomes for its CD19 CAR T-cell candidate GLPG5101 in high-risk mantle cell lymphoma, with rapid manufacturing timelines and limited severe toxicities. On the same occasion, Galapagos confirmed plans to wind down its cell therapy activities, while remaining open to a potential sale, highlighting a contrast between promising clinical results and a retreat from...

Mama's Creations (MAMA) just posted its Q3 2026 numbers, with revenue of about $47.3 million, basic EPS of $0.01, and net income of $0.5 million, setting the stage for investors to parse how the growth story is holding up. The company has seen quarterly revenue move from $31.5 million in Q3 2025 to $47.3 million in the latest quarter, while EPS shifted from $0.01 to $0.01 and net income from $0.4 million to $0.5 million, giving a clearer read on how much of the top line is actually making it...

Academy Sports and Outdoors (ASO) has posted its Q3 2026 numbers with revenue of about $1.4 billion and EPS of roughly $1.07, giving investors a fresh read on how demand is holding up across the year. The company has seen revenue move from roughly $1.34 billion in Q3 2025 to about $1.38 billion in Q3 2026, while EPS shifted from around $0.94 to $1.07 over the same period, setting a clear baseline for how the business is tracking through the current cycle as margins do the heavy lifting in the...